View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Catalent|13 July 2017

Flexible Manufacturing

Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson's.

Catalent's launch of Safinamide

Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson’s.

Zambon s.p.A. entrusted Catalent as its partner for timely development and launch of Safinamide under the brand name Xadago® to a worldwide target market.

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology